European shares were unchanged on Friday, as losses in heavyweight healthcare shares were countered by an advance in oil and ...

The Sensex dropped 502 points on Friday to close at 81,758, while the Nifty slipped 143 points to end below the 25,000 mark ...

The Nikkei 225 has fallen 0.2%, while the Hang Seng index is 0.3% higher. The FTSE 100 index is seen opening about 21 points ...

The fallers board was led by WPP, which slumped by 16% to its lowest level since 2009 after the marketing and advertising ...

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

Incyte INCY has put up a good performance in the past three months. Shares of the company have gained 9.2% against the industry’s decline of 1.3%. The stock has also outperformed the sector in the ...

For new and old investors, taking full advantage of the stock market and investing ... its share price will decline as well. Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, ...

GlaxoSmithKline Pharmaceuticals, with its shares currently priced at Rs 3,292.30, remains a key stock to watch, particularly for those invested in or tracking the NIFTY MIDCAP 150 index.

GSK plc (NYSE: GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval of Nucala for chronic obstructive pulmonary disease (COPD) and a ...

Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its sales and profits to improve.

The main aim of stock picking is to find the market-beating stocks. But the main game is to find enough winners to more than offset the losers So we wouldn't blame long term GSK plc (LON:GSK) ...